Market Research Reports Global Kidney Cancer Treatment Drugs Market Report | Page 2

Major players operating in the market are focusing on clinical collaboration and commercial expansion
to tap several opportunities present in the market. Stringent governmental regulation makes this
market tough for small players. Small player in the market are launching several bio-similar products in
order to satisfy increasing demand from the emerging economies of the globe.
AVEO Pharmaceuticals, Inc. announced data from the final analysis of its Phase 2 randomized
discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the
VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma
(RCC). Data showed that the median progression-free survival (PFS) achieved among all patients (both
clear cell and non-clear histologies) treated with tivozanib was 11.7 months and, as previously
presented, 14.8 months among those with clear cell RCC who had undergone nephrectomy, which is the
same patient population being evaluated in AVEO's ongoing Phase 3 trial comparing tivozanib to
sorafenib (Nexavar), called TIVO-1.
Kidney Cancer Treatment Drugs Market Covers the Table of Contents With Segments, Key Players And
Region. Based on Product Type, Kidney Cancer Treatment Drugs Market is sub segmented into
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2). On
the Basis of Application, Market is sub segmented into Hospitals, Research Institutes, Diagnostic
Centers.
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on
“Global Kidney Cancer Treatment Drugs Market Report 2019”
https://www.businessindustryreports.com/buy-now/160343/single .
MajorPlayers profiled in the Kidney Cancer Treatment Drugs Market report incorporate:
Amgen/Allergan, Argos Therapeutics, AstraZeneca, Aveo Pharmaceuticals, Bayer, Exelixis, Incyte, Merck,
Roche, Pfizer, Bristol-Myers Squibb, Eisai, Prometheus Labs, Novartis
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Kidney Cancer Treatment Drugs in these regions, from 2014 to 2023
(forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America.
The report is a compilation of first-hand information, qualitative and quantitative assessment by
industry analysts, inputs from industry experts and industry participants across the value chain. The
report provides in-depth analysis of parent market trends, macro-economic indicators and governing
factors along with market attractiveness as per segments. The report also maps the qualitative impact of
various market factors on market segments and geographies.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation
(Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost
Analysis, and Conclusion.
Report contents include